Explores a new method for oligonucleotide labeling, suggesting potential for easier delivery to cells.
The introduction of chemical modifications into oligonucleotides enhances backbone stability against nuclease degradation and improves biological activity. Although achieving cell-, tissue-, and organ-specific delivery remains challenging, conjugation to triantennary N-acetylgalactosamine (triGalNAc) ligands enables receptor-mediated delivery of nucleic acids to hepatocytes. TriGalNAc ligands are usually attached to the termini of therapeutic oligonucleotides via labor-intensive methods that require specialized equipment and expertise. As an alternative, we explored enzymatic labeling of oligonucleotides with triantennary GalNAc ligands, providing a strategy that is compatible with any sequence and does not require complex chemical synthesis. Two complementary strategies for triGalNAc labeling were employed. In the first, we modified the γ-phosphate of ATP with a triGalNAc moiety and tested its kinase-catalyzed transfer to the 5' termini of oligonucleotides. In the second, we functionalized the 3' position of an LNA nucleoside triphosphate with a triGalNAc residue and used this analog for template-independent 3'-end labeling of oligonucleotides. While kinases do not seem to fully tolerate the presence of such a bulky residue on ATP, template-independent polymerases readily incorporate the modified nucleotide at the 3'-end of DNA and RNA oligonucleotides. Overall, this work represents a first step towards the development of a universal, enzymatic triGalNAc-labeling method for therapeutic oligonucleotides.
No takes yet. Share an insight, caveat, or question.
Bizat et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: